BioMarin Pharmaceutical (BMRN) Q3 2024 earnings summary

Executive summary

• Achieved 28% year-over-year revenue growth in Q3 2024, reaching $746 million, driven by strong performance in VOXZOGO and enzyme therapies, with net income more than doubling to $106 million.

• VOXZOGO revenues grew 54% year-over-year to $190 million in Q3, with global patient growth to over 3,800 children and expansion planned into 20+ additional countries by 2027.

• Enzyme therapies portfolio revenues increased 27% year-over-year in Q3, with strong growth in Aldurazyme, Naglazyme, and Vimizim.

• Strategic restructuring included business unit realignment, portfolio assessment, and a reduction of about 395 employees to enhance efficiency and profitability.

• Leadership team strengthened with new appointments, supporting innovation and growth strategy.

Financial highlights

• Q3 2024 total revenue was $746 million, up 28% year-over-year; net product revenues were $733.9 million.

• Q3 GAAP net income was $106 million, up from $40.4 million in Q3 2023; GAAP diluted EPS was $0.55 (+162%), non-GAAP diluted EPS was $0.91 (+98%).

• Operating cash flow for Q3 was $221 million, up 63% year-over-year.

• Gross margin was 75%, impacted by product mix and ROCTAVIAN inventory reserves.

• Total cash and investments at quarter-end were approximately $1.5 billion.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $2.79–$2.825 billion, with non-GAAP operating margin at 26.5–27.5% and non-GAAP diluted EPS at $3.25–$3.35.

• Long-term targets reaffirmed: $4 billion revenue by 2027, 40%+ non-GAAP operating margin from 2026, $1.25 billion+ annual operating cash flow by 2027, and mid-teen CAGR through 2034.

• Gross margin expected to increase modestly as product mix shifts toward higher-margin products.

• R&D expenses projected to rise due to new VOXZOGO indications and early pipeline programs.

• SG&A expenses expected to remain consistent as market expansion is offset by corporate initiatives.